MedTrace Logo

HD IL-2 + Vemurafenib in Patients With BRAF Mutation Positive Metastatic Melanoma

NCT01683188 · Status: TERMINATED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 53

Last updated 2021-02-01

No results posted yet for this study

Summary

This is a research study to evaluate treatment of metastatic melanoma patients with a combination of drugs. The combination being studied is vemurafenib (also known as Zelboraf®) and High Dose Interleukin-2 (abbreviated as HD IL-2 and known as Proleukin®). The combination of vemurafenib and HD IL-2 immunotherapy may enhance the response.

Conditions

Interventions

DRUG

vemurafenib + HD IL-2

Sponsors & Collaborators

  • Prometheus Laboratories

    collaborator INDUSTRY

  • Clinigen, Inc.

    lead INDUSTRY

Principal Investigators

  • Tharak Rao, MD · Prometheus Laboratories

Study Design

Allocation
NON_RANDOMIZED
Purpose
OTHER
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-08-31
Primary Completion
2014-11-30
Completion
2014-11-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01683188 on ClinicalTrials.gov